UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Transdermal drug pharmacokinetics in man: Interindividual variability and partial prediction

International journal of pharmaceutics, 2009-02, Vol.367 (1), p.1-15

2009

Volltextzugriff (PDF)

Application of quality by design approach for intranasal delivery of rivastigmine loaded solid lipid nanoparticles: Effect on formulation and characterization parameters

European journal of pharmaceutical sciences, 2015-10, Vol.78, p.54-66

2015

Volltextzugriff (PDF)

Apigenin-rivastigmine hybrids as multi-target-directed liagnds for the treatment of Alzheimer’s disease

European journal of medicinal chemistry, 2020-02, Vol.187, p.111958, Article 111958

2020

Volltextzugriff (PDF)

Design, synthesis, biological evaluation, and molecular modeling studies of chalcone-rivastigmine hybrids as cholinesterase inhibitors

Bioorganic & medicinal chemistry, 2017-01, Vol.25 (1), p.360-371

2017

Volltextzugriff (PDF)

Rivastigmine for gait stability in patients with Parkinson's disease (ReSPonD): a randomised, double-blind, placebo-controlled, phase 2 trial

Lancet neurology, 2016-03, Vol.15 (3), p.249-258

2016

Volltextzugriff (PDF)

Pharmacokinetic and pharmacodynamic evaluation of nasal liposome and nanoparticle based rivastigmine formulations in acute and chronic models of Alzheimer’s disease

Naunyn-Schmiedeberg's archives of pharmacology, 2021-08, Vol.394 (8), p.1737-1755

2021

Volltextzugriff (PDF)

Comparative evaluation of rivastigmine permeation from a transdermal system in the Franz cell using synthetic membranes and pig ear skin with in vivo-in vitro correlation

International journal of pharmaceutics, 2016-10, Vol.512 (1), p.234-241

2016

Volltextzugriff (PDF)

Esophagectasis Related to Rivastigmine

Internal Medicine, 2019, pp.2137-18

2019

Volltextzugriff (PDF)

An update on the utility and safety of cholinesterase inhibitors for the treatment of Alzheimer's disease

Expert opinion on drug safety, 2020-02, Vol.19 (2), p.147-157

2020

Volltextzugriff (PDF)

Systematic development of lectin conjugated microspheres for nose-to-brain delivery of rivastigmine for the treatment of Alzheimer’s disease

Biomedicine & pharmacotherapy, 2021-09, Vol.141, p.111829-111829, Article 111829

2021

Volltextzugriff (PDF)

Cholinesterase inhibitors for vascular dementia and other vascular cognitive impairments: a network meta-analysis

Cochrane database of systematic reviews, 2021-02, Vol.2 (2), p.CD013306

2021

Volltextzugriff (PDF)

Nose to brain microemulsion-based drug delivery system of rivastigmine: formulation and ex-vivo characterization

Drug delivery, 2015-10, Vol.22 (7), p.918-930

2015

Volltextzugriff (PDF)

Rivastigmine als ondersteuning bij het dilemma van de behandeling van hallucinaties optredend bij ziekte van Parkinson

Tijdschrift voor gerontologie en geriatrie, 2024-02, Vol.37 (3), p.127-130

2024

Volltextzugriff (PDF)

Development of a nanoprecipitation method for the entrapment of a very water soluble drug into Eudragit RL nanoparticles

Research in pharmaceutical sciences, 2017-01, Vol.12 (1), p.1-14

2017

Volltextzugriff (PDF)

Rivastigmine: the advantages of dual inhibition of acetylcholinesterase and butyrylcholinesterase and its role in subcortical vascular dementia and Parkinson's disease dementia

Clinical interventions in aging, 2017-01, Vol.12, p.697-707

2017

Volltextzugriff (PDF)

Absolute bioavailability and safety of a novel rivastigmine nasal spray in healthy elderly individuals

British journal of clinical pharmacology, 2017-03, Vol.83 (3), p.510-516

2017

Volltextzugriff (PDF)

Development and validation of high-performance liquid chromatography method for the simultaneous quantification of rivastigmine hydrogen tartrate and asiaticoside co-loaded in niosomes: A Box–Behnken design approach

Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2024-07, Vol.1241, p.124170, Article 124170

2024

Volltextzugriff (PDF)

Implantable trilayer microneedle transdermal delivery system to enhance bioavailability and brain delivery of rivastigmine for Alzheimer treatment: A proof-of-concept study

European journal of pharmaceutics and biopharmaceutics, 2024-08, Vol.201, p.114382, Article 114382

2024

Volltextzugriff (PDF)

Discovery of novel rivastigmine-hydroxycinnamic acid hybrids as multi-targeted agents for Alzheimer's disease

European journal of medicinal chemistry, 2017-01, Vol.125, p.784-792

2017

Volltextzugriff (PDF)

Nature-based molecules combined with rivastigmine: A symbiotic approach for the synthesis of new agents against Alzheimer's disease

European journal of medicinal chemistry, 2017-12, Vol.141, p.232-239

2017

Volltextzugriff (PDF)

Rivastigmine ameliorates gentamicin experimentally induced acute renal toxicity

International immunopharmacology, 2023-01, Vol.114, p.109492, Article 109492

2023

Volltextzugriff (PDF)

MARK4 Inhibited by AChE Inhibitors, Donepezil and Rivastigmine Tartrate: Insights into Alzheimer's Disease Therapy

Biomolecules (Basel, Switzerland), 2020-05, Vol.10 (5), p.789

2020

Volltextzugriff (PDF)

Tailored Modeling of Rivastigmine Derivatives as Dual Acetylcholinesterase and Butyrylcholinesterase Inhibitors for Alzheimer's Disease Treatment

Chemistry & biodiversity, 2021-11, Vol.18 (11), p.e2100361-n/a

2021

Volltextzugriff (PDF)

Antidementia medication acetylcholinesterase inhibitors have therapeutic benefits on osteoporotic bone by attenuating osteoclastogenesis and bone resorption

Journal of cellular physiology, 2023-08, Vol.238 (8), p.1823-1835

2023

Volltextzugriff (PDF)

Rivastigmine does not alter cocaine-induced subjective effects or self-administration

Pharmacology, biochemistry and behavior, 2019-10, Vol.185, p.172758-172758, Article 172758

2019

Volltextzugriff (PDF)

1 – 25 von 1.975

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(1.748)
Mit Volltextzugriff
(1.450)

Publikationsform

3 weitere anzeigen...

Weniger anzeigen...

Sprache

12 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Rivastigmine
(1.803)
Science & Technology
(1.481)
Life Sciences & Biomedicine
(1.390)
Humans
(1.186)
Alzheimer's Disease
(754)
Alzheimer Disease - Drug Therapy
(730)
Cholinesterase Inhibitors - Therapeutic Use
(667)
Male
(645)
Aged
(589)
Female
(573)
Pharmacology & Pharmacy
(525)
Neurosciences & Neurology
(498)
Donepezil
(466)
Phenylcarbamates - Therapeutic Use
(415)
Biological And Medical Sciences
(386)
Medical Sciences
(372)
Dementia
(365)
Galantamine
(332)
Clinical Neurology
(331)
Aged, 80 And Over
(316)

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

MEDLINE
(1.384)
Ingenta
(867)
Ovid
(750)
EZB Electronic Journals Library
(627)
IngentaConnect Journals
(448)
Wiley Online Library
(300)
Access via ScienceDirect (Elsevier)
(274)
Springer Journals
(252)
Standalone journals
(243)
Wiley Online Library Full Collection 2018
(233)
Elsevier Journal Backfiles on ScienceDirect (DFG Nationallizenzen)
(197)
Taylor & Francis Journals
(150)
Taylor & Francis
(117)
Nexis Uni
(105)
Taylor & Francis Online
(103)
SpringerLINK Contemporary (Konsortium Baden-Württemberg)
(100)
SAGE Journals
(64)
Psychology & Behavioral Sciences Collection
(55)
Ebook Central Perpetual and DDA
(43)
eBooks on EBSCOhost
(41)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(3)
... seit 90 Tagen
(9)

Menü

Weitere Dienste

Einstellungen

Transdermal drug pharmacokinetics in man: Interindividual variability and partial prediction

Application of quality by design approach for intranasal delivery of rivastigmine loaded solid lipid nanoparticles: Effect on formulation and characterization parameters

Apigenin-rivastigmine hybrids as multi-target-directed liagnds for the treatment of Alzheimer’s disease

Design, synthesis, biological evaluation, and molecular modeling studies of chalcone-rivastigmine hybrids as cholinesterase inhibitors

Rivastigmine for gait stability in patients with Parkinson's disease (ReSPonD): a randomised, double-blind, placebo-controlled, phase 2 trial

Pharmacokinetic and pharmacodynamic evaluation of nasal liposome and nanoparticle based rivastigmine formulations in acute and chronic models of Alzheimer’s disease

Comparative evaluation of rivastigmine permeation from a transdermal system in the Franz cell using synthetic membranes and pig ear skin with in vivo-in vitro correlation

Esophagectasis Related to Rivastigmine

An update on the utility and safety of cholinesterase inhibitors for the treatment of Alzheimer's disease

Systematic development of lectin conjugated microspheres for nose-to-brain delivery of rivastigmine for the treatment of Alzheimer’s disease

Cholinesterase inhibitors for vascular dementia and other vascular cognitive impairments: a network meta-analysis

Nose to brain microemulsion-based drug delivery system of rivastigmine: formulation and ex-vivo characterization

Rivastigmine als ondersteuning bij het dilemma van de behandeling van hallucinaties optredend bij ziekte van Parkinson

Development of a nanoprecipitation method for the entrapment of a very water soluble drug into Eudragit RL nanoparticles

Rivastigmine: the advantages of dual inhibition of acetylcholinesterase and butyrylcholinesterase and its role in subcortical vascular dementia and Parkinson's disease dementia

Absolute bioavailability and safety of a novel rivastigmine nasal spray in healthy elderly individuals

Development and validation of high-performance liquid chromatography method for the simultaneous quantification of rivastigmine hydrogen tartrate and asiaticoside co-loaded in niosomes: A Box–Behnken design approach

Implantable trilayer microneedle transdermal delivery system to enhance bioavailability and brain delivery of rivastigmine for Alzheimer treatment: A proof-of-concept study

Discovery of novel rivastigmine-hydroxycinnamic acid hybrids as multi-targeted agents for Alzheimer's disease

Nature-based molecules combined with rivastigmine: A symbiotic approach for the synthesis of new agents against Alzheimer's disease

Rivastigmine ameliorates gentamicin experimentally induced acute renal toxicity

MARK4 Inhibited by AChE Inhibitors, Donepezil and Rivastigmine Tartrate: Insights into Alzheimer's Disease Therapy

Tailored Modeling of Rivastigmine Derivatives as Dual Acetylcholinesterase and Butyrylcholinesterase Inhibitors for Alzheimer's Disease Treatment

Antidementia medication acetylcholinesterase inhibitors have therapeutic benefits on osteoporotic bone by attenuating osteoclastogenesis and bone resorption

Rivastigmine does not alter cocaine-induced subjective effects or self-administration

Suchergebnisse filtern